46. The composition for use in a method of treatment or the method of treatment of any one of the preceding claims, wherein the nanoparticles of amorphous magnesium-substituted calcium phosphate have mean diameters in a range between 20 nm and 350 nm.

47. The composition for use in a method of treatment or the method of treatment of claim 46, wherein at least 75% of the nanoparticles of amorphous magnesium-substituted calcium phosphate have a mean diameter in the range.

~~47.~~ 48 An agent capable of promoting PD-L1 expression in antigen presenting immune cells of intestinal lymphoid follicles for use in a method of treating Crohn's disease.

~~48.~~ 49 A composition for use in a method of diagnosis or imaging, wherein the composition comprises amorphous magnesium-substituted calcium phosphate (AMCP), wherein the amorphous magnesium-substituted calcium phosphate entraps a detectable moiety.

~~49.~~ 50 The composition for use in a method of diagnosis or imaging of claim 48, wherein the amorphous magnesium-substituted calcium phosphate the composition is capable of delivering the cargo material to a site of interest in the gastrointestinal tract.

~~49.~~ 51 The composition for use in a method of diagnosis of claim 48, wherein the detectable moiety comprises nanoparticles, such as metal-based nanoparticles or metal oxo-hydroxide nanoparticles.

~~50.~~ 52 A process for producing amorphous magnesium-substituted calcium phosphate compositions that contain entrapped biologically active cargo material, the process comprising:

(a) providing a solution comprising calcium ions (Ca^{2+}), magnesium ions (Mg^{2+}) and a solution comprising phosphate ions (PO_4^{3-}), wherein one or both of the solutions comprise one or more

biologically active cargo materials;

(b) mixing the solution comprising calcium ions (Ca^{2+}), magnesium ions (Mg^{2+})with the solution comprising phosphate ions (PO_4^{2-}) to precipitate amorphous magnesium-substituted calcium phosphate in which the biologically active cargo material is entrapped;

(c) recovering the amorphous magnesium-substituted calcium phosphate; and

(d) optionally washing and drying the amorphous magnesium-substituted calcium phosphate.

~~51.~~53 The process of claim 50, wherein the solution comprising calcium ions (Ca^{2+}), magnesium ions (Mg^{2+}) and biologically active cargo molecules is buffered at a pH of at least 8.0.

~~52.~~54 The process of claim 50 or claim 51, wherein the biologically active cargo material increases the stability of the amorphous magnesium-substituted calcium phosphate to conversion to crystalline phases of calcium phosphate as compared to corresponding compositions that do not include entrapped cargo material.

~~53.~~55 The process of any one of claims 50 to 52, wherein the washing and drying step comprises reslurrying the composition in acetone and drying the washed composition using centrifugation.

~~54.~~56 The process of claim 53, wherein the washing and drying steps are repeated twice.

~~55.~~57 The process of any one of claims 50 to 54, wherein the pH during steps (a) and/or (b) is greater than 8.0.

~~56.~~58 The process of any one of claims 50 to 55, wherein the buffer is Tris, HEPES, BICINE, TRICINE or a citric acid buffer, or an amino acid such as lysine or glycine.

~~57.~~59 The process of any one of claims 50 to 56, further